Hosted on MSN

Morgan Stanley upgrades DexCom (DXCM), cites undervalued recovery and G7 margin potential

DexCom Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy in 2026. On December 2, Morgan Stanley upgraded DexCom to Overweight from Equal Weight with a price target of $75, which was up from ...
Medscape

Dexcom’s 15-day CGM Adds Wear Time, Accuracy to Current G7

The Dexcom 15-day G7 continuous glucose monitor (CGM) is accurate and safe for use up to 15.5 days in adults with diabetes. Currently under review by the US Food and Drug Administration, it is more ...
MD&M East

Incoming Dexcom CEO Addresses G7 User Challenges

Numerous comments on a Facebook group called “Dexcom G7 – Issues and Complaints” has brought to light a problem that users are referring to as “goose necking.” MD+DI learned more about this issue – ...
Medscape

Dexcom Issues Recall for G7, ONE+ Apps for Software Issues

Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...
CNET

The FDA Just Cleared the Dexcom G7 15-Day, the Longest-Lasting CGM Wearable

The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users. Taylor Leamey wrote about all things wellness for CNET, specializing in ...
Nasdaq

DexCom Shares May Rise as G7 15-Day CGM System Gets FDA Clearance

DexCom, Inc. DXCM recently announced the FDA clearance for its 15-day wear G7 Continuous Glucose Monitoring (CGM) system, the longest-lasting and most accurate CGM approved in the United States. This ...
Seeking Alpha

DexCom May Be The Most Underrated Growth Story In Healthcare

DexCom receives a BUY rating due to strong growth, expanding margins, and the launch of Stelo, the first OTC CGM for non-insulin users. DXCM raised its 2025 outlook, targeting $4.6B+ in revenue, 62% ...